Patents by Inventor Elisabeth SOUHAMI

Elisabeth SOUHAMI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION
    Publication number: 20230037934
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: April 28, 2022
    Publication date: February 9, 2023
    Inventors: Elisabeth Souhami, Louise Silvestre
  • INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION
    Publication number: 20220031811
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: May 3, 2021
    Publication date: February 3, 2022
    Inventors: Elisabeth Souhami, Louise Silvestre
  • Insulin glargine/lixisenatide fixed ratio formulation
    Patent number: 11026999
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: June 8, 2021
    Inventors: Elisabeth Souhami, Louise Silvestre
  • INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION
    Publication number: 20210128692
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: August 17, 2020
    Publication date: May 6, 2021
    Inventors: Elisabeth Souhami, Louise Silvestre
  • TREATMENT OF TYPE 2 DIABETES MELLITUS
    Publication number: 20210093698
    Abstract: The present invention relates to a pharmaceutical combination, comprising (a) a pharmaceutical formulation comprising (i) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (ii) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (b) an SGLT2 inhibitor, or/and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 9, 2020
    Publication date: April 1, 2021
    Inventors: Elisabeth NIEMÖLLER, Elisabeth SOUHAMI
  • INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION
    Publication number: 20200038488
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: April 3, 2019
    Publication date: February 6, 2020
    Inventors: Elisabeth Souhami, Louise Silvestre
  • INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION
    Publication number: 20190381145
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: April 17, 2019
    Publication date: December 19, 2019
    Inventors: Elisabeth Souhami, Louise Silvestre
  • Treatment type 2 diabetes mellitus patients
    Patent number: 10434147
    Abstract: A pharmaceutical combination for use in glycemic control in a type 2 diabetes mellitus patient, said combination comprising (i) lixisenatide or/and a pharmaceutically acceptable salt thereof, (ii) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (iii) optionally metformin or/and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: October 8, 2019
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Christine Roy, Elisabeth Souhami, Nacima Demil, Jenny Ye
  • Insulin Glargine/Lixisenatide Fixed Ratio Formulation
    Publication number: 20190060411
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: August 10, 2018
    Publication date: February 28, 2019
    Inventors: Elisabeth Souhami, Louise Silvestre
  • Insulin glargine/lixisenatide fixed ratio formulation
    Publication number: 20180133290
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: July 24, 2017
    Publication date: May 17, 2018
    Inventors: Elisabeth Souhami, Louise Silvestre
  • Insulin glargine/lixisenatide fixed ratio formulation
    Patent number: 9950039
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: April 24, 2018
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Elisabeth Souhami, Louise Silvestre
  • Treatment Type 2 Diabetes Mellitus Patients
    Publication number: 20180092965
    Abstract: A pharmaceutical combination for use in glycemic control in a type 2 diabetes mellitus patient, said combination comprising (i) lixisenatide or/and a pharmaceutically acceptable salt thereof, (ii) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (iii) optionally metformin or/and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 11, 2017
    Publication date: April 5, 2018
    Inventors: Christine Roy, Elisabeth Souhami, Nacima Demil, Jenny Ye
  • METHOD OF TREATMENT OF DIABETES TYPE 2 COMPRISING ADD-ON THERAPY TO INSULIN GLARGINE AND METFORMIN
    Publication number: 20170136094
    Abstract: A method for the treatment of diabetes mellitus type 2 comprising administering (d) desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, (e) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (f) metformin or/and a pharmaceutically acceptable salt thereof, to a subject in need thereof.
    Type: Application
    Filed: September 26, 2016
    Publication date: May 18, 2017
    Inventors: Louise SILVESTRE, Elisabeth SOUHAMI, Xiaodan WEI
  • Treatment Type 2 Diabetes Mellitus Patients
    Publication number: 20160287674
    Abstract: A pharmaceutical combination for use in glycemic control in a type 2 diabetes mellitus patient, said combination comprising (i) lixisenatide or/and a pharmaceutically acceptable salt thereof, (ii) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (iii) optionally metformin or/and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 11, 2016
    Publication date: October 6, 2016
    Inventors: Christine Roy, Elisabeth Souhami, Nacima Demil, Jenny Ye
  • Insulin glargine/lixisenatide fixed ratio formulation
    Publication number: 20160199452
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: December 10, 2015
    Publication date: July 14, 2016
    Inventors: Elisabeth Souhami, Louise Silvestre
  • Insulin glargine/lixisenatide fixed ratio formulation
    Publication number: 20140371141
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: June 13, 2014
    Publication date: December 18, 2014
    Inventors: Elisabeth Souhami, Louise Silvestre
  • TREATMENT PROTOCOL OF DIABETES TYPE 2
    Publication number: 20130296236
    Abstract: The present invention refers to a treatment protocol for diabetes type 2 patients.
    Type: Application
    Filed: October 26, 2012
    Publication date: November 7, 2013
    Inventors: Louise SILVESTRE, Elisabeth SOUHAMI, Xiaodan WEI
  • METHOD OF TREATMENT OF DIABETES TYPE 2 COMPRISING ADD-ON THERAPY TO INSULIN GLARGINE AND METFORMIN
    Publication number: 20110118178
    Abstract: A method for the treatment of diabetes mellitus type 2 comprising administering (d) desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, (e) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (f) metformin or/and a pharmaceutically acceptable salt thereof, to a subject in need thereof.
    Type: Application
    Filed: November 13, 2009
    Publication date: May 19, 2011
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Louise SILVESTRE, Elisabeth SOUHAMI, Xiaodan WEI